Blood clotting is one of the most fundamental protective mechanisms in human physiology. The ability of the blood to clot appropriately prevents excessive bleeding from injury and supports the vascular integrity that life depends on. But in the context of fertility and IVF, clotting that is too aggressive or poorly regulated can silently impair the intricate vascular processes that support embryo implantation, early placental development, and the maintenance of a healthy pregnancy.
Thrombophilia, a tendency toward abnormal or excessive blood clotting, is present in a meaningful proportion of women with recurrent pregnancy loss and unexplained IVF implantation failure. Many of these women are entirely unaware that they carry a condition that may be contributing to their fertility challenges, because thrombophilias often produce no symptoms in the absence of pregnancy or surgery.
Understanding what thrombophilia is, which conditions fall under this umbrella, how they affect IVF outcomes, and what treatment options are available gives couples with a potential clotting disorder the clinical knowledge they need to pursue appropriate investigation and management before their next cycle.
What Thrombophilia Is and How It Affects Pregnancy
Thrombophilia refers to a group of inherited or acquired conditions that alter the balance of the coagulation system in a way that increases the tendency for abnormal blood clot formation. In non-pregnant individuals, many thrombophilias produce no clinical problems and are identified only through targeted blood testing. In pregnancy, however, the naturally pro-coagulant state of the maternal circulation amplifies the clotting tendency of thrombophilic conditions, increasing the risk of thrombosis in the placental vasculature.
The placenta is a highly vascular structure whose function depends entirely on adequate blood flow through an intricate network of maternal and fetal blood vessels. Microscopic clots in the maternal decidual vessels that supply blood to the developing placenta impair this flow, reducing nutrient and oxygen delivery to the embryo and early fetus. In the earliest stages of pregnancy, impaired placental blood flow can prevent successful implantation entirely. Slightly later, it can cause early pregnancy loss. In ongoing pregnancies, placental insufficiency driven by thrombophilic coagulopathy can cause growth restriction, placental abruption, and other serious complications.
Inherited Thrombophilias
Several inherited genetic variants alter specific components of the coagulation cascade in ways that increase clotting tendency and have been studied in the context of pregnancy loss and IVF outcomes.
Factor V Leiden mutation is the most common inherited thrombophilia, present in approximately 5 percent of European populations. It produces resistance to activated protein C, a natural anticoagulant, resulting in a persistent pro-thrombotic tendency. The heterozygous form carries a moderate increase in thrombosis risk that is amplified by pregnancy. The homozygous form carries a substantially higher risk.
Prothrombin gene mutation, also known as Factor II G20210A mutation, increases circulating prothrombin levels and is associated with an elevated risk of venous thrombosis and adverse pregnancy outcomes in some studies.
MTHFR gene variants, which affect folate metabolism and homocysteine levels, have been extensively studied in the context of pregnancy loss and recurrent IVF failure. The clinical significance of isolated MTHFR variants, particularly heterozygous C677T, in the absence of elevated homocysteine remains debated, and current evidence does not support MTHFR variant status as an independent indication for anticoagulant treatment. However, ensuring adequate folate and B vitamin intake to support normal homocysteine metabolism is appropriate in carriers.
Protein C and protein S deficiencies, antithrombin deficiency, and other less common inherited thrombophilias complete the spectrum of inherited conditions that may be identified on comprehensive thrombophilia screening.
Acquired Thrombophilia: Antiphospholipid Syndrome
Antiphospholipid syndrome is the most clinically significant acquired thrombophilia in the context of fertility and IVF. As discussed in the recurrent pregnancy loss guide earlier in this series, antiphospholipid syndrome involves the production of antibodies that bind to phospholipid-protein complexes and promote thrombosis and placental dysfunction.
The clinical manifestations of antiphospholipid syndrome in the reproductive context include recurrent pregnancy loss, particularly second-trimester losses that are less likely to be explained by chromosomal abnormality than first-trimester losses, preeclampsia, fetal growth restriction, placental abruption, and unexplained IVF implantation failure despite good embryo quality.
Diagnosis requires positive results on at least two occasions, twelve or more weeks apart, for one or more of the recognised antiphospholipid antibodies: anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies, and lupus anticoagulant. A single positive result may represent a transient finding rather than a persistent autoimmune condition and is insufficient for diagnosis.
Thrombophilia Testing Before IVF
Thrombophilia screening is not universally recommended for all IVF patients, and the appropriate indications for testing vary between guidelines and between clinical contexts. However, there are clear patient populations for whom thrombophilia screening before IVF is clinically well-justified.
Women with a personal or family history of venous thromboembolism including deep vein thrombosis or pulmonary embolism should be screened for inherited thrombophilia before beginning IVF, both to guide management during treatment and to inform anticoagulation planning during pregnancy.
Women with recurrent pregnancy loss, particularly those with two or more losses, should be screened for antiphospholipid syndrome as a standard component of the recurrent loss workup, as described in guidelines from major reproductive medicine organisations globally.
Women with unexplained IVF implantation failure despite good embryo quality and an optimised uterine environment are candidates for thrombophilia screening as part of a broader implantation failure investigation, particularly when other causes have been excluded.
Women with a personal history of preeclampsia, placental abruption, or severe fetal growth restriction in a previous pregnancy, whether naturally conceived or through IVF, may benefit from thrombophilia screening before their next treatment attempt.
A comprehensive thrombophilia panel typically includes testing for Factor V Leiden mutation, prothrombin gene mutation, protein C and protein S activity, antithrombin activity, MTHFR genotype, homocysteine levels, and the full antiphospholipid antibody panel. Timing of testing is important, as some tests including protein C, protein S, and antithrombin are affected by acute thrombosis, pregnancy, and anticoagulant therapy and should be performed when the patient is not in any of these states.
Management of Thrombophilia in IVF
The management of identified thrombophilia in IVF depends on the specific condition identified, its severity, and the patient’s clinical history.
Antiphospholipid syndrome with a confirmed diagnosis and a history of pregnancy loss or thrombosis is treated with a combination of low-dose aspirin and low molecular weight heparin during IVF and throughout pregnancy. This combination therapy has strong evidence supporting its use and has been shown to significantly improve live birth rates in antiphospholipid syndrome patients compared to no treatment or aspirin alone.
Low-dose aspirin alone is sometimes used in antiphospholipid syndrome patients with milder disease profiles or in patients with positive antibodies but without the full clinical syndrome, though the evidence for this approach is less robust than for the combination therapy.
For inherited thrombophilias, management during IVF and pregnancy is more individualised and depends on the specific variant, whether it is heterozygous or homozygous, and the patient’s personal and family history of thrombotic events. Women with high-risk inherited thrombophilias or a personal history of thrombosis will generally require anticoagulation during IVF and throughout pregnancy. Those with lower-risk variants and no personal history may be managed with increased monitoring and aspirin rather than full anticoagulation.
Low molecular weight heparin, the anticoagulant most commonly used in this context, is administered as a once or twice daily subcutaneous injection and is generally safe throughout pregnancy with appropriate monitoring. It does not cross the placenta and does not carry the fetal risks associated with warfarin.
Seeking guidance from an experienced IVF Center in Jaipur that screens for thrombophilia as part of a comprehensive implantation failure or recurrent loss workup and that coordinates management with haematology expertise where appropriate ensures that this clinically significant and treatable contributor to IVF failure is identified and addressed rather than overlooked.
Final Thoughts
Thrombophilia is a silent condition that can profoundly affect IVF outcomes and pregnancy maintenance without producing any obvious symptoms in daily life. For couples with unexplained implantation failure, recurrent pregnancy loss, or a personal or family history of clotting disorders, thrombophilia screening before IVF is a targeted and clinically valuable investigation that deserves to be part of a thorough pre-treatment workup.
For expert fertility care that incorporates comprehensive clotting disorder screening and evidence-based management into your IVF treatment plan, a trusted IVF Specialist in Jaipur with specific expertise in complex fertility cases and access to haematology collaboration provides the complete clinical support that patients with thrombophilia-related fertility challenges genuinely need.
